Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1975]

Tepotinib in second line NSCLC treatment

Dr Antonio Passaro and Prof Raffaele Califano

Tepotinib in second line NSCLC treatment ( Dr Antonio Passaro and Prof Raffaele Califano )

Tucatinib added to trastuzumab and pertuzumab improves PFS in first-line HER2...

Dr Erika Hamilton - Sarah Cannon Research Institute, Nashville, USA

Tucatinib added to trastuzumab and pertuzumab improves PFS in first-line HER2-positive metastatic breast cancer ( Dr Erika Hamilton - Sarah Cannon Research Institute, Nashville, USA )

Sacituzumab govitecan improves quality of life in untreated advanced TNBC

Dr Kevin Punie - Ziekenhuis aan de Stroom, Antwerp, Belgium

Sacituzumab govitecan improves quality of life in untreated advanced TNBC ( Dr Kevin Punie - Ziekenhuis aan de Stroom, Antwerp, Belgium )

Pirtobrutinib significantly improves PFS in treatment-naïve CLL/SLL compared to...

Prof Wojciech Jurczak - Maria Sklodowska-Curie National Research Institute of...

Pirtobrutinib significantly improves PFS in treatment-naïve CLL/SLL compared to bendamustine plus rituximab ( Prof Wojciech Jurczak - Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland )

Comment: Pirtobrutinib improves PFS in treatment-naïve CLL/SLL compared to...

Dr Tycel Phillips - City of Hope National Medical Center, Duarte, USA

Comment: Pirtobrutinib improves PFS in treatment-naïve CLL/SLL compared to bendamustine/rituximab ( Dr Tycel Phillips - City of Hope National Medical Center, Duarte, USA )

Glofitamab, venetoclax, and lenalidomide combination shows promising efficacy...

Dr Tycel Phillips - City of Hope National Medical Center, Duarte, USA

Glofitamab, venetoclax, and lenalidomide combination shows promising efficacy in high-risk mantle cell lymphoma ( Dr Tycel Phillips - City of Hope National Medical Center, Duarte, USA )

Longer follow-up shows promising PFS + MRD negativity for mosunetuzumab use in...

Dr John Burke - Rocky Mountain Cancer Centers, Aurora, USA

Longer follow-up shows promising PFS + MRD negativity for mosunetuzumab use in untreated high tumour burden follicular lymphoma ( Dr John Burke - Rocky Mountain Cancer Centers, Aurora, USA )

Off-the-shelf in vivo CAR-T therapy KLN-1010 shows early MRD-negative responses...

Prof Joy Ho - Royal Prince Alfred Hospital, Sydney, Australia

$Off-the-shelf in vivo CAR-T therapy KLN-1010 shows early MRD-negative responses in relapsed/refractory multiple myeloma ( Prof Joy Ho - Royal Prince Alfred Hospital, Sydney, Australia )$

Zamtocabtagene autoleucel improves event-free survival vs standard of care in...

Prof Peter Borchmann - University Hospital of Cologne, Cologne, Germany

Zamtocabtagene autoleucel improves event-free survival vs standard of care in second-line r/r LBCL ( Prof Peter Borchmann - University Hospital of Cologne, Cologne, Germany )

Anitocabtagene autoleucel achieves deep and durable responses in relapsed...

Dr Krina Patel - MD Anderson Cancer Center, Houston, USA

$Anitocabtagene autoleucel achieves deep and durable responses in relapsed/refractory multiple myelomas ( Dr Krina Patel - MD Anderson Cancer Center, Houston, USA )$

Talquetamab plus teclistamab shows promise in true extramedullary multiple...

Dr Shahzad Raza - Cleveland Clinic, Cleveland, USA

Talquetamab plus teclistamab shows promise in true extramedullary multiple myeloma ( Dr Shahzad Raza - Cleveland Clinic, Cleveland, USA )

Choosing Wisely: Managing resectable colorectal liver metastases

Dr Christopher Jackson - University of Otago, Otago, New Zeland

Choosing Wisely: Managing resectable colorectal liver metastases ( Dr Christopher Jackson - University of Otago, Otago, New Zeland )

More from ecancer